cervic
cancer
cacx
strongli
associ
human
papillomaviru
hpv
infect
particularli
hpv
type
constitut
express
hpv
protein
cacx
make
attract
target
ctl
base
immunotherapi
howev
cervic
carcinoma
may
featur
eg
antigen
process
defect
limit
effect
hpv
specif
ctl
furthermor
vaccin
develop
concentr
hpv
type
clear
whether
vaccin
could
induc
ctl
abl
crossreact
relat
oncogen
hpv
type
eg
investig
potenti
import
paramet
vitro
use
ctl
specif
abl
kill
varieti
cacx
cell
line
includ
suspect
caski
known
antigen
process
defect
low
hpv
dna
copi
number
siha
also
abl
cross
react
relat
peptid
analysi
suggest
cross
reactiv
relat
peptid
influenc
tcr
contact
residu
certain
threshold
peptid
bind
hpv
crossreact
confirm
whole
protein
level
also
abl
recogn
endogen
process
form
result
suggest
would
use
epitop
immunotherapi
hpv
tumour
despit
difficult
gener
ctl
respons
vaccin
emphas
need
definit
novel
epitop
effici
vaccin
strategi
cervic
cancer
cacx
second
common
caus
cancer
women
world
wide
premalign
cervic
intraepitheli
neoplasia
associ
hpv
infect
develop
countri
case
occur
princip
femal
cancer
dna
hpv
particularli
found
cacx
patient
protein
consist
retain
express
cervic
tumor
cell
give
viru
transform
properti
hpv
defin
low
high
risk
highrisk
type
associ
invas
cervic
cancer
low
risk
type
associ
wart
hpv
type
consist
classifi
highrisk
type
type
divid
class
type
c
hpv
typespecif
preval
vari
geograph
worldwid
type
domin
noncaucasian
popul
domin
infect
rate
hpv
type
vari
countri
countri
ie
found
case
philippin
morocco
accord
et
al
infect
caus
type
suggest
vaccin
common
type
could
prevent
case
cacx
geograph
variat
hpv
preval
show
target
popul
ie
popul
bear
highest
burden
cacx
requir
incorpor
hpv
type
commonli
occur
vaccin
design
littl
work
done
examin
cross
reactiv
oncogen
hpv
type
tcell
level
although
extens
crossreact
cell
demonstr
previous
shown
possibl
detect
ctl
specif
blood
patient
cacx
blood
healthi
donor
ctl
mediat
lysi
b
cell
endogen
express
protein
hpv
transform
cervic
cancer
cell
line
caski
sinc
peptid
homolog
peptid
phylogenet
relat
type
use
ctl
investig
vitro
potenti
crossrecognit
hpv
type
invitrogen
corpor
paisley
scotland
uk
alway
use
follow
addit
hepe
sigmaaldrich
co
ltd
pool
uk
mm
lglutamin
invitrogen
corpor
iuml
penicillin
gml
streptomycin
invitrogen
corpor
known
tcm
cultur
cell
media
supplement
pool
human
ab
serum
nation
blood
transfus
servic
pontyclun
wale
known
rab
dmem
mgl
glucos
pyridoxin
hcl
invitrogen
corpor
alway
use
follow
addit
hepe
mm
lglutamin
iuml
penicillin
gml
streptomycin
cell
line
b
lymphoblastoid
cell
line
transfect
express
hlaa
allel
provid
professor
aj
mcmichael
institut
molecular
medicin
oxford
uk
maintain
rpmi
contain
fetal
calf
serum
fc
invitrogen
corpor
gml
invitrogen
corpor
contain
fc
use
maintain
follow
cell
line
cell
contain
antigen
process
defect
due
homozyg
delet
mhc
class
ii
region
locat
chromosom
result
low
densiti
hlaa
cell
surfac
caski
hlaa
posit
cervic
carcinoma
cell
line
express
protein
ecacc
hlaa
posit
breast
epitheli
carcinoma
cell
line
kind
gift
l
sherman
scripp
clinic
la
jolla
ca
ecacc
cell
line
creat
transfect
epitheli
cell
line
free
known
papillomaviru
sequenc
atcc
plasmid
contain
whole
genom
cell
line
maintain
dmem
contain
fc
siha
atcc
adher
squamou
cell
cervic
carcinoma
cell
line
copi
integr
cell
genom
also
maintain
media
hpv
peptid
analogu
synthes
immun
system
ltd
paignton
uk
purifi
revers
phase
hplc
puriti
ident
sequenc
tabl
peptid
confirm
mass
spectrometri
gener
monospecif
polyclon
ctl
line
monospecif
polyclon
ctl
line
gener
describ
previous
briefli
specif
ctl
line
gener
patient
stage
iib
cervic
cancer
singl
cell
sort
base
tricoloranti
caltag
burlingam
ca
tetram
pe
label
doubl
stain
carri
use
facsvantag
bectondickinson
mountain
view
ca
tcell
clone
peptid
gener
describ
previous
briefli
memori
ctl
peptid
identifi
patient
invas
carcinoma
follow
vitro
restimul
peptid
ctl
line
clone
limit
dilut
plate
use
irradi
allogen
peripher
blood
mononuclear
cell
pbmc
feeder
phytohaemagglutinin
pha
bio
stat
ltd
stockport
uk
lymphocult
biotest
ag
dreieich
germani
clone
expand
flask
use
irradi
allogen
pbmc
pha
chiron
uk
ltd
harefield
middlesex
uk
transfect
cell
line
establish
investig
recognit
full
length
protein
variou
hpv
type
cell
line
chosen
transfect
experi
varieti
reason
hpv
neg
cervic
carcinoma
cell
line
point
mutat
previous
transfect
express
work
laboratori
other
shown
cell
line
low
level
express
molecul
involv
antigen
process
present
eg
tap
hlaa
amplifi
cdna
kindli
suppli
describ
tabl
ii
polymeras
chain
reaction
pcr
use
specif
primer
detail
tabl
iii
obtain
invitrogen
corpor
pcr
product
clone
topo
pcr
clone
vector
accord
topo
ta
clone
kit
manufactur
instruct
invitrogen
corpor
insert
cut
topo
pcr
clone
vector
use
restrict
endonucleas
bamhi
ligat
express
vector
invitrogen
corpor
ligat
transform
bacteria
result
clone
screen
restrict
digest
sequenc
isol
clone
correctli
express
sequenc
confirm
insert
ident
publish
data
carri
transfect
cell
plate
well
plate
greiner
bioon
ltd
stonehous
gloucestershir
uk
hr
addit
dotap
liposom
transfect
reagent
roch
diagnost
ltd
lew
east
sussex
uk
accord
manufactur
instruct
g
dna
fortyeight
hour
posttransfect
express
cell
select
gml
blasticidin
invitrogen
corpor
cultur
maintain
select
media
cell
use
assay
less
passag
siha
cell
transfect
use
dotap
lyposom
transfect
reagent
plasmid
confer
neomycin
resist
invitrogen
corpor
clone
hlaa
briefli
cell
plate
plate
g
dna
l
dotap
per
well
cell
select
gml
hr
post
transfect
abund
cell
sort
dako
cytom
moflo
hlaa
express
cytotox
measur
standard
hr
cr
releas
assay
describ
previous
target
cell
puls
vari
dose
peptid
analogu
hr
label
hr
cr
na
cro
amersham
bioscienc
littl
chalfont
uk
previous
cytotox
hpv
measur
use
recombin
vaccinia
viru
tahpv
gift
xenova
plc
cambridg
uk
tahpv
shown
express
hpv
antigen
western
blot
recognit
hpvspecif
ctl
cell
infect
vaccinia
virus
moi
maximum
hr
cr
label
method
also
use
infect
siha
cell
recombin
vaccinia
viru
encod
hla
recognit
natur
endogen
process
antigen
assess
use
cell
line
caski
label
hr
cr
cell
line
contain
hpv
antigen
use
control
hr
incub
radioact
count
obtain
plate
liquid
scintil
count
microbeta
trilux
liquid
scintil
luminesc
counter
wallac
miltonkeyn
uk
clone
seed
triplic
well
densiti
cellswel
multiscreen
plate
millipor
corpor
bedford
coat
overnight
catch
antibodi
mabtech
ab
sweden
wildtyp
transfect
ad
ratio
transfect
cell
incub
hr
elispot
analysi
perform
accord
manufactur
instruct
posit
control
peptid
ad
concentr
gml
antigen
present
cell
cocktail
also
creat
contain
concavalin
gml
sigmaaldrich
st
loui
mo
ionomycin
ngml
merck
bioscienc
ltd
beeston
nottingham
uk
pha
gml
bio
stat
ltd
pokewe
mitogen
ngml
sigmaaldrich
show
optim
secret
condit
analysi
spot
carri
use
dissect
stereomicroscop
magnif
time
independ
observ
peptid
bind
studi
carri
describ
previous
nijman
et
al
briefli
cell
wash
incub
peptid
overnight
tcm
co
cell
stain
hybridoma
supernat
specif
hlaa
min
cell
wash
twice
cold
fcspb
fitclabel
rabbit
antimous
igg
dakocytom
ltd
denmark
hous
eli
cambridgeshir
uk
dilut
ad
min
fluoresc
ratio
calcul
follow
mean
fluoresc
experiment
samplemean
fluoresc
background
measur
stabil
peptidemhc
interact
use
modif
method
describ
feltkamp
et
al
briefli
cell
incub
gml
peptid
gml
b
microglobulin
sigmaaldrich
overnight
co
cell
wash
tcm
resuspend
ml
tcm
return
incub
aliquot
taken
point
subsequ
hr
stain
level
hlaa
express
time
kill
sever
cervic
carcinoma
cell
line
includ
antigen
process
defect
unlik
ctl
two
differ
ctl
clone
use
investig
effect
antigen
process
defect
hpv
dna
copi
number
suscept
carcinoma
cell
lyse
specif
specif
abil
recogn
hlaa
peptid
shown
abil
lyse
transfect
puls
peptid
fig
also
recogn
peptid
endogen
form
present
hlaa
transform
cell
line
caski
fig
western
blot
analysi
carri
laboratori
shown
caski
low
level
antigen
process
present
molecul
lmp
tap
kill
caski
cell
therefor
suggest
gener
epitop
limit
low
level
express
protein
support
data
observ
cell
western
blot
analysi
shown
cell
almost
undetect
low
level
lmp
tap
cell
transfect
express
hpv
recogn
lyse
contrast
activ
clone
unabl
kill
caski
cell
cr
releas
assay
unless
cell
puls
exogen
peptid
fig
suggest
gener
epitop
may
limit
antigen
process
defect
caski
cell
despit
report
caski
copi
hpv
genom
support
result
seen
cell
cell
low
level
molecul
involv
antigen
process
present
kill
effect
low
hpv
dna
copi
number
suscept
cervic
carcinoma
cell
kill
assess
use
cell
line
siha
infect
recombin
vaccinia
viru
express
hlaa
transfect
express
protein
siha
cell
express
maximum
copi
hpv
therefor
express
antigen
interest
predict
low
cervic
carcinoma
cell
line
kill
ctl
result
suggest
may
better
epitop
ctlbase
immunotherapi
peptid
sequenc
peptid
relat
hpv
type
similar
tabl
therefor
investig
abil
ctl
recogn
target
puls
peptid
indic
cross
reactiv
chromium
releas
assay
seen
abil
kill
target
puls
rang
dose
ymld
lqpett
gml
fig
also
abl
kill
target
puls
rang
dose
peptid
yildlqpett
fig
level
lysi
high
peptid
dose
gml
compar
seen
peptid
concentr
gml
howev
level
lysi
greatli
reduc
although
signific
lysi
still
observ
howev
target
puls
peptid
yvldlqpeat
fig
kill
regardless
peptid
dose
therefor
show
cross
reactiv
peptid
hpv
type
investig
import
amino
acid
substitut
peptid
sequenc
affect
recognit
ctl
seri
analogu
peptid
synthes
map
specif
blcl
target
puls
analogu
yvldlqpett
fig
significantli
lyse
dose
peptid
albeit
lower
level
peptid
howev
analogu
yildlqpeat
recogn
peptid
concentr
test
fig
data
suggest
conserv
amino
acid
substitut
posit
peptid
littl
effect
recognit
therefor
nonrecognit
probabl
due
nonconserv
amino
acid
chang
test
use
analogu
peptid
ymldlqpeat
contain
amino
acid
peptid
alter
peptid
ymldlqpeat
recogn
dose
puls
onto
cell
chromium
releas
assay
fig
suggest
peptid
neg
effect
recognit
data
describ
suggest
nonconserv
amino
acid
substitut
threonin
alanin
posit
result
lack
peptid
recognit
attempt
assess
due
lack
bind
due
interact
tcr
crude
measur
peptid
bind
carri
fig
influenza
matrix
peptid
use
posit
control
known
bind
strongli
hlaa
seen
figur
peptid
bind
equal
well
peptid
conserv
amino
acid
substitut
posit
yildlqpettand
analogu
yvldlqpett
show
measur
bind
compar
peptid
level
bind
reduc
analogu
peptid
conserv
amino
acid
substitut
posit
nonconserv
substitut
posit
yvldlqpeat
analogu
yildlqpeat
show
greatli
reduc
level
bind
hlaa
molecul
compar
peptid
fig
case
bond
hlaa
molecul
peptid
briefli
cell
incub
variou
peptid
gml
stain
monoclon
antibodi
specif
hlaa
influenza
matrix
peptid
known
bind
strongli
hla
allel
use
posit
control
peptid
bind
hlaa
stabli
greater
hr
stabl
apart
peptid
hpv
peptid
ymldlqpeat
show
bind
stabil
greater
hr
fig
peptid
bound
well
slightli
better
peptid
substitut
posit
fig
therefor
nonrecognit
peptid
like
due
interact
amino
acid
posit
tcr
overal
result
demonstr
conserv
amino
acid
substitut
posit
dramat
affect
recognit
ctl
analogu
despit
reduct
peptid
bind
peptid
simultan
substitut
posit
abolish
ctl
recognit
analogu
reduc
peptid
bind
result
ctl
recognit
despit
peptid
bind
suggest
posit
act
primarili
tcr
contact
residu
ctl
recognit
peptid
chang
residu
analogu
therefor
lack
recognit
ctl
due
effect
tcr
contact
residu
peptid
bind
howev
conserv
amino
acid
differ
posit
allow
crossreact
shown
ctl
abil
recogn
peptid
hpv
type
peptid
level
limit
import
decid
investig
cross
reactiv
exist
level
full
length
protein
ie
cross
reactiv
epitop
gener
endogen
hpv
neg
cervic
carcinoma
cell
line
transfect
use
dotap
express
full
length
hpv
type
antigen
specif
tcell
respons
measur
elispot
assay
seen
full
genom
cell
line
transfect
gener
laboratori
stimul
greater
proport
cell
secret
cocultur
wildtyp
cell
fig
augment
respons
seen
cocultur
transfect
howev
incub
posit
transfect
fail
result
substanti
increas
secret
cell
data
confirm
peptid
endogen
process
present
transfect
fig
also
suggest
endogen
process
present
cell
line
studi
demonstr
epitop
specif
differ
ctl
line
ctl
specif
abl
kill
hpv
transform
cervic
carcinoma
cell
line
caski
cell
line
transfect
express
antigen
process
defect
cell
line
siha
transfect
express
hlaa
express
dna
copi
contrast
gener
unabl
kill
cell
line
unless
puls
exogen
peptid
infect
tahpv
increas
level
endogen
antigen
although
precis
level
endogen
antigen
could
quantit
caski
siha
line
like
low
recent
studi
suggest
despit
differ
dna
copi
number
hpv
gene
express
similarli
low
cell
line
nevertheless
result
suggest
epitop
would
use
vaccin
gener
ctl
capabl
kill
target
express
endogen
hpv
antigen
use
ctl
tool
investig
potenti
cross
reactiv
peptid
phylogenet
relat
hpv
type
peptid
hpv
similar
chang
anchor
posit
chang
posit
seen
sequenc
result
loss
recognit
high
peptid
dose
gml
reduc
still
signific
recognit
seen
peptid
dose
lower
howev
alter
amino
acid
posit
seen
peptid
result
abolit
recognit
gener
synthet
analogu
peptid
ymldlqpeat
abl
demonstr
amino
acid
posit
vital
peptid
recognit
use
crude
measur
peptid
bind
hlaa
abl
show
lack
recognit
due
loss
abil
bind
hla
molecul
present
due
conform
chang
affect
recognit
tcr
cross
reactiv
peptid
level
import
unless
cross
reactiv
epitop
produc
endogen
demonstr
case
follow
transfect
cervic
epitheli
cell
line
express
full
length
hpv
type
howev
limit
studi
method
use
show
abil
peptid
bind
hlaa
bind
assay
crude
result
could
therefor
said
indic
true
interact
also
cours
work
becam
increasingli
difficult
expand
maintain
age
limit
number
avail
ctl
therefor
use
elispot
measur
interact
transfect
rather
chromium
releas
assay
previou
experi
investig
potenti
epitop
immunotherapi
tcell
epitop
identifi
hpv
protein
nonhlaa
restrict
epitop
defin
protein
two
epitop
found
restrict
epitop
shown
produc
endogen
blcl
infect
vaccinia
viru
encod
epitop
may
therapeut
potenti
howev
hla
rare
hla
allel
figur
kill
transfect
express
fulllength
hpv
type
ctl
assess
abil
kill
transfect
express
full
length
hpv
type
cell
transfect
use
liposom
transfect
reagent
dotap
select
grow
media
contain
gml
blasticidin
number
antigen
specif
cell
analyz
elispot
respond
cell
incub
follow
stimul
transfect
laboratori
express
elispot
develop
hr
cell
mix
ratio
total
number
responderswel
transfect
stimul
ctl
produc
significantli
higher
amount
compar
wildtyp
cell
incub
cultur
condit
incub
peptid
gml
produc
spot
posit
control
cocktail
contain
pha
pma
concavalin
ionomycin
spot
seen
data
shown
caucasian
popul
recognit
cancer
cell
document
cross
reactiv
also
demonstr
cell
specif
hpv
nonhpv
peptid
cell
healthi
individu
stimul
dendrit
cell
dc
puls
abl
recogn
stimul
peptid
unrel
peptid
coronaviru
crossreact
epitop
also
produc
endogen
author
argu
epitop
may
therefor
ideal
assess
anti
hpv
respons
may
explain
detect
anti
hpv
cell
seen
healthi
individu
would
interest
test
whether
ctl
clone
could
cross
react
coronaviru
ctl
immunotherapi
promis
strategi
fight
diseas
shown
studi
mice
human
cancer
patient
protein
constitut
express
make
attract
target
immunotherapi
previou
work
shown
presenc
low
frequenc
ctl
blood
patient
cervic
cancer
current
result
suggest
ctl
epitop
would
use
immunotherapi
ctl
produc
vitro
stimul
protocol
effect
target
express
endogen
antigen
confirm
independ
recent
studi
schruer
et
al
use
dc
puls
modifi
peptid
ymldlqpetv
gener
ctl
clone
healthi
donor
clone
kill
target
express
exogen
endogen
process
epitop
present
either
caski
cell
cell
line
deriv
posit
biopsi
hlaa
posit
individu
howev
despit
employ
varieti
vaccin
vaccin
strategi
gener
ctl
epitop
seen
clinic
trial
exampl
multipl
studi
use
tahpv
live
recombin
vaccinia
viru
encod
hpv
respons
seen
even
use
sensit
detect
techniqu
elispot
despit
number
vaccin
vaccin
regim
respons
seen
major
peopl
post
vaccin
respons
deriv
peptid
demonstr
muderspach
cowork
studi
murakami
colleagu
use
fusion
protein
vitro
puls
autolog
dc
stimul
cell
vitro
respons
seen
peptid
puls
onto
target
cell
produc
endogen
although
epitop
use
gener
ctl
abl
lyse
target
express
endogen
antigen
show
specif
peptid
relat
hpv
type
lack
respons
seen
clinic
trial
patient
immun
full
length
suggest
immun
peptid
directli
would
benefici
emphas
need
addit
epitop
gener
ctl
restrict
multipl
hla
molecul
identifi
ctl
epitop
could
induc
amplifi
vivo
use
prime
boost
techniqu
